Join Bryan Lowery, VP & GM mRNA Vaccine and pDNA Operations, as he unveils our new, cutting-edge biomanufacturing facility, set to open its doors in late 2023. […]
Resources
On-Demand Webinar
For decades, microbial fermentation has been used for the commercialization of biologics, with the fermentation of recombinant proteins such as insulin in stainless steel bioreactors as large as 100,000 L.[…]
Virtual Tour
For decades, microbial fermentation has been used for the commercialization of biologics, with the fermentation of recombinant proteins such as insulin in stainless steel bioreactors as large as 100,000 L. […]
White Paper
Large-scale single-use fermentation technology using aerobic microbial expression systems offers an excellent complement to stainless steel bioreactors for clinical-to-commercial scale production of recombinant proteins. […]
Article
The development and production of mRNA therapeutics and vaccines requires expertise in both chemical synthesis and microbial fermentation. […]
Interview
For the final interview of the Road to 50 States road trip campaign, Oliver Technow and Heather Delage of BIOVECTRA met with Nigel at CPhI in Milan to discuss the company’s unique capability to offer both small and large molecule biologic products to their clients. […]
White Paper
High-potency drugs derived from natural products command a large and growing market share in the pharmaceutical industry. The rich diversity of potent natural products necessitates a range of manufacturing demands. […]
Article
BIOVECTRA’s Scott Doncaster, Neil Morrison, and Cameron Graham discuss the company’s addition of single-use fermenter technology […]
Article
Much of the innovation occurring in the pharmaceutical industry today is achieved by smaller pharma/biotech firms with limited commercial manufacturing experience […]
Article
The production of increasingly complex small molecule APIs is challenging drug makers. CDMOs with multiple capabilities are needed to develop efficient routes to synthesize these […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.